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ABSTRACT
Vitiligo development in melanoma patients during immunotherapy is a favorable prognostic sign and
indicates breakage of tolerance against melanocytic/melanoma antigens. We investigated a novel
immunotherapeutic approach of the skin-depigmenting compound monobenzone synergizing with
imiquimod in inducing antimelanoma immunity and melanoma regression. Stage III-IV melanoma patients
with non-resectable cutaneous melanoma metastases were treated with monobenzone and imiquimod
(MI) therapy applied locally to cutaneous metastases and adjacent skin during 12 weeks, or longer.
Twenty-one of 25 enrolled patients were evaluable for clinical assessment at 12 weeks. MI therapy was
well-tolerated. Partial regression of cutaneous metastases was observed in 8 patients and stable disease in
1 patient, reaching the statistical endpoint of treatment efﬁcacy. Continued treatment induced clinical
response in 11 patients, including complete responses in three patients. Seven patients developed vitiligo-
like depigmentation on areas of skin that were not treated with MI therapy, indicating a systemic effect of
MI therapy. Melanoma-speciﬁc antibody responses were induced in 7 of 17 patients tested and
melanoma-speciﬁc CD8CT-cell responses in 11 of 15 patients tested. These systemic immune responses
were signiﬁcantly increased during therapy as compared to baseline in responding patients. This study
shows that MI therapy induces local and systemic anti-melanoma immunity and local regression of
cutaneous metastases in 38% of patients, or 52% during prolonged therapy. This study provides proof-of-
concept of MI therapy, a low-cost, broadly applicable and well-tolerated treatment for cutaneous
melanoma metastases, attractive for further clinical investigation.
KEYWORDS
Melanoma; immunotherapy;
vitiligo; cutaneous
metastases
Introduction
Melanoma patients undergoing immunotherapy can develop
autoimmunity against melanocytes resulting in vitiligo-like
depigmentation.1 Our systematic review and meta-analysis of
clinical immunotherapy studies over the past 18 years showed
that vitiligo development in advanced melanoma patients dur-
ing immunotherapy is associated with prolonged progression-
free and overall survival (disease progression Hazard Ratio
(HR) 0.51, p < 0.005; risk of death HR 0.25, p < 0.003).2 This
type of depigmentation in melanoma patients indicates break-
age of tolerance against melanocytic antigens, leading to clini-
cally active anti-melanocyte/melanoma immunity, consisting
of melanoma-reactive T-cells and antibody responses.3,4
We developed a new type of immunotherapy for melanoma
using the vitiligo-inducing agent monobenzone combined with
imiquimod and/or CpG oligodeoxynucleotide. Our preclinical
results showed synergy of these compounds in speciﬁcally
inducing antimelanoma immunity and tumor growth inhibi-
tion.5 Monobenzone (monobenzyl ether of hydroquinone) is a
potent skin-bleaching agent that can induce vitiligo.6,7 It has
been used in the past to achieve complete depigmentation in
patients with vitiligo universalis.6 Importantly, monobenzone-
induced depigmentation also occurs at distant, non-exposed
skin sites in human beings, indicating the occurrence of sys-
temic reactivity against melanocytes. The mechanism of action
of monobenzone therapy consists of the selective interaction of
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monobenzone with tyrosinase, the rate-limiting enzyme in mel-
anin synthesis, in both melanocytes and melanoma cells.8,9 This
interaction leads to the inactivation of the tyrosinase enzyme
and the formation of the reactive quinone product that is toxic
to the melanocyte, and binds to melanosomal proteins, which
increases the immunogenicity of these proteins. Together with
the production of reactive oxygen species and the release of
exosomes by monobenzone-exposed pigmented cells, this leads
to the induction of systemic melanocyte/melanoma antigen-
speciﬁc immunity.8,9 Monobenzone acts synergistically in com-
bination with the Toll-like receptor (TLR) agonists imiquimod
(Aldara) and CpG, to activate dendritic cells and induces
effective immunity against established murine melanoma.5
Here, we present the ﬁrst clinical study of monobenzone/
imiquimod (MI) therapy in melanoma patients, exploring its
immunizing capacity and local clinical effect against cutaneous
melanoma metastases. Cutaneous metastases, including local
relapse, satellite metastases or in-transit metastases, occur in
approximately 5% of melanoma patients and they imply a neg-
ative prognostic outcome comparable to lymph node metasta-
ses.10 Stage III melanoma patients with extensive cutaneous
metastases not eligible for surgery have limited treatment
options, as treatment of all cutaneous lesions in an affected
skin area, especially microscopic lesions, remains difﬁcult. Sev-
eral local strategies such as carbon dioxide laser ablation, radio-
therapy/hyperthermia, electrochemotherapy, topical immune
modiﬁers, diphencyprone and intralesional therapy with cyto-
kines have been applied but clinical results vary.11-17 Isolated
limb perfusion (ILP) or infusion (ILI) can be effective but also
has signiﬁcant toxicity. Injections with oncolytic viruses pro-
ducing GM-CSF (T-Vec) show promising results, indicating
that local immune stimulating therapy can translate into dura-
ble clinical responses in these patients.18 However, this is an
intensive treatment of biweekly intralesional injections, which
can be painful for the patient and requires a post-injection
observation of several hours in the hospital and extensive safety
precautions limiting its use in non-specialized medical centers.
MI therapy may represent an attractive option for topical
treatment of cutaneous melanoma metastases, including large
numbers of small lesions that are not surgically resectable, con-
sidering its targeted antimelanoma immunizing mechanism of
action preventing relapse in preclinical studies and with a low
toxicity proﬁle.
The objectives of this clinical trial were to assess clinical efﬁ-
cacy of MI therapy on cutaneous metastases in stage III-IV
melanoma patients and its capacity to induce local and sys-
temic antimelanoma immunity in patients.
Results
Patient characteristics
Twenty-ﬁve patients were accrued for the study in order to
reach the required number of 21 evaluable patients according
to the study design. All patients were monitored for systemic
disease progression during the study as standard of care. Four
patients were not evaluable for local efﬁcacy of MI therapy: one
patient decided to stop treatment for personal reasons; three
patients were diagnosed with distant metastases during the
study and were referred back to their treating physician.
Twenty-one patients did not experience systemic disease pro-
gression and were evaluable at the primary endpoint. Clinical
and demographic characteristics of these 21 patients are shown
in Table 1. All patients, except for patient MI-02, had under-
gone prior lymph node dissection. Table 1 shows the sites of
metastases at study entry. Patients with cutaneous metastases
not eligible for surgery were included, which presented as mul-
tiple small cutaneous lesions located on the extremities. Seven-
teen patients of the 21 evaluable patients received at least 12
weeks of MI therapy. Four patients of 21 patients stopped after
6 weeks due to local progression and were evaluated as PD at
the primary endpoint. Thirteen patients continued MI therapy
after 12 weeks. The median duration of therapy was 16 weeks.
Toxicity
Adverse events causally related to MI therapy are listed in
Table 2. MI therapy was well tolerated. Almost all adverse
events were grade 1 or 2 and resolved within 2–3 days, most
were skin related (erythema, rash, pruritus, ulceration, crusta,
edema, burning sensation) and few were systemic (transient
fatigue, headache, nausea and ﬂu-like symptoms). One patient
developed erysipelas requiring hospitalization (grade 3) and 1
patient (MI-02) developed a contact hypersensitivity reaction
to monobenzone within the ﬁrst 6 weeks which required dis-
continuation of monobenzone in both patients. Hypersensitiv-
ity symptoms were relieved with topical steroids. Patient MI-25
interrupted MI treatment for 10 days due to an itchy skin rash
but restarted thereafter and continued MI therapy for 12 weeks.
No serious adverse events occurred and no patient left the
study for safety reasons.
Clinical responses
Local response of cutaneous metastases and response duration
were evaluated in 21 patients (Table 1). These 21 patients did
not develop systemic disease progression during MI therapy
until the primary endpoint at 12 weeks. The study protocol was
designed to include patients with inoperable cutaneous metas-
tases, which mostly present as multiple small cutaneous lesions
within a certain body area. MI therapy was therefore evaluated
as a treatment option for these lesions. All treated lesions were
smaller than 1 cm in diameter (non-target lesions), and tumor
responses were assessed by the number of lesions relative to
baseline, as described in the Patients and Methods section. In
case of doubt, when clinically only hyperpigmentation was seen
in a lesion that had regressed in size but did not completely dis-
appear, the lesion was biopsied for histological analysis. The
response rate was 38%, with 8 of 21 patients achieving PR after
12 weeks of treatment. In addition, one patient had stable dis-
ease (SD) after 12 weeks. This study thereby reached the statis-
tical endpoint of local treatment efﬁcacy to warrant further
studies of MI therapy. Prolonged MI therapy improved the
therapeutic effect, as shown by further decrease in number of
lesions in 11 patients (response rate 52%). This response rate
included 2 patients (MI-16 and MI- 24) who did not show a
local clinical response at 12 weeks and continued MI therapy
because of lack of alternative treatment options, and responded
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to prolonged MI therapy. The relative change in number of
lesions in the 21 evaluable patients at t D 12 and the best
response during MI therapy (BR) are presented in Figure 1A.
The median clinical response duration in the 11 responding
patients upon prolonged MI therapy was 6 months (Figure 1B).
The median local progression-free survival during MI therapy
and follow up without other therapy of all patients was 13 weeks.
One stage IV patient (MI-04), having stable disease at t D
12 weeks, continued MI therapy during 72 weeks and achieved
CR by MI therapy only. After this study, he subsequently devel-
oped lymph node metastases in the right groin in December
2012, and received ipilimumab followed by pembrolizumab ther-
apy. In March 2014 this lesion was excised and he experiences
tumor-free survival. Patient MI-09 continued MI therapy for
32 weeks and achieved a CR. Patient MI-24 (PD) did not show
any regression of cutaneous lesions until week 14 of MI therapy,
but achieved a CR at 36 weeks of continued treatment. Likewise,
patient MI-16 (PD) showed PR from 16 weeks of MI therapy
onwards which continued up to 28 weeks. Patient MI-08 experi-
enced regression of multiple cutaneous metastases in the head,
neck and continued therapy up to 36 weeks (Figure 2A). Seven
of the treated patients developed vitiligo-like depigmentation on
areas of skin that were not treated with MI therapy (Figure 2B),
indicating a systemic effect of MI therapy.3,4
Patient 25 had only 1 lesion left after 12 weeks of MI ther-
apy. After this study, he continued with 5 times per week imi-
quimod (Aldara) treatment only. Since then he had 2 new in
transit metastases in the treated area, which were excised, and
is free of tumor since March 2016.
Induction of antimelanoma immune responses
MI therapy induced speciﬁc antibody responses against
MART-1, gp100 and tyrosinase in 7 of 17 patients who com-
pleted at least 12 weeks of MI therapy (Figure 3). None of the 4
nonresponding patients receiving only 6 weeks of MI therapy
developed an antibody response. Antibody responses were
found in 6 out of 11 patients with a clinical response to therapy
at 12 weeks or during prolonged MI therapy (Figure 3A). Only
1 patient (MI-15) out of 6 nonresponding patients, who com-
pleted 12 weeks of MI therapy, developed a melanoma-reactive
antibody response (Figure 3B). A time-related increase of mela-
noma-speciﬁc antibody levels was observed in most patients
and lasted for 10 weeks to one year. Antibody index levels of all
patients analyzed were increased at 12 weeks as compared to
baseline (baseline median 1.01, interquartile range (IQR) 0.93–
1.04 vs median at 12 weeks 1.20, IQR 0.95–1.38, p < 0.024).
This signiﬁcant increase was found in responders (baseline
median 1.01, IQR 0.92–1.03 vs median at 12 weeks 1.31, IQR
0.97–1.67, p < 0.002), and was not signiﬁcant in nonrespond-
ing, nonresponding patients (baseline median 1.01, IQR 0.95–
1.05 vs median at 12 weeks 1.07, IQR 0.92–1.03, p>0.57).
Figure 1. Local clinical responses of treated cutaneous metastases. A, Relative
change (%) in number of cutaneous metastases at the primary endpoint after
12 weeks (upper panel) and the best response during MI therapy (lower panel) rela-
tive to baseline. The clinical response at 12 weeks was calculated by the formula:
(L12-L0)/L0100%, in which L0 is the number of lesions at baseline (t D 0) and L12
the number of lesions at t D 12. The best response during MI therapy was calcu-
lated by the formula: (Lx-L0)/L0100%, in which Lx is the least number of lesions
during MI therapy, excluding t D 6 weeks. Red bars represent nonresponding
patients who stopped after 6 weeks. patient MI-13 developed target lesions (PD).
B, Clinical response duration during prolonged MI therapy (blue bars) and after MI
therapy cessation without additional therapy (white bars).
Table 2. Adverse events by Common Toxicity Criteria.
grade I/II grade III/IV
skin and subcutaneous tissue disorder
maculopapular rash 8 0
pruritus 4 0
skin ulceration 5 0
skin infection 6 1
dry skin 1 0
depigmentation 7 0
skin other
erythema 14 0
crusta 7 0
contact hypersensitivity 1 0
edema 4 0
burning sensation 2 0
general adverse events
myalgia 2 0
fatigue 9 0
ﬂue like symptoms 3 0
headache 7 0
nausea 6 0
malaise 1 0
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The induction of systemic T-cell responses was analyzed by
HLA-peptide tetramer analysis of T-cells recognizing mela-
noma antigens MART-1, gp100 or tyrosinase presented by
HLA-A1, -A2 or -A3. Both peripheral blood mononuclear cells
(PBMC) and cultured peripheral blood lymphocytes (PBL)
taken at baseline, 12 weeks and at later time points during pro-
longed therapy were analyzed. Examples of the ﬂow cytometric
analyses are shown in Figure S1. Fifteen patients who com-
pleted at least 12 weeks of MI therapy and were typed HLA-
A1, -A2 and/or -A3 were analyzed (Figure 4 and S2). Concern-
ing the other 6 patients: patients MI-07 and MI-15 did not
have an HLA type including HLA- A1, -A2 or -A3 and
ﬁg 4could therefore not be analyzed by the panel of HLA-pep-
tide tetramers; 4 patients who received only 6 weeks of therapy
were not included in the T cell analyses. Since the kinetics of T-
cell response induction or ampliﬁcation varied among patients,
we compared the maximal T-cell response level reached during
MI therapy (at 12 weeks and later time points) with baseline
per patient for each tetramer (Figure 4 and S2). This maximal
T-cell response level was reached between 12 and 24 weeks of
MI therapy. Part of the T-cell reactivity was already present at
baseline, which is known to occur in melanoma, and these
responses either increased or stabilized during MI therapy in
the majority of cases. PBMC analyses showed increased mela-
noma-reactive T-cell responses upon MI therapy (at percen-
tages higher than 0.1% of CD8C T cells), as compared to
baseline, against various melanoma antigens in 5 responding
patients and 3 nonresponding patients (Figure 4). In PBL
expanded from PBMC in a culture without speciﬁc antigenic
stimulus, increased T-cell reactivity was found in 8 responding
patients and 3 nonresponding patients upon MI therapy
(Figure S2). The PBL data also includes patients MI-14 and
MI-24, of whom PBMC were not evaluable. Although systemic
T-cell responses were found at low levels, pooled analysis of the
percentages of melanoma-speciﬁc T-cells in the PBMC showed
a signiﬁcant increase upon MI therapy as compared to baseline
(median 0.10, interquartile range (IQR) 0.03–0.31 vs median
0.17, IQR 0.06–0.47, p < 0.032). These T-cell response levels
were signiﬁcantly increased in responding patients (median
0.10, IQR 0.03–0.34 vs 0.18, IQR 0.07–0.51, p < 0.016), but not
in nonresponding patients (median 0.10, IQR 0.02–0.24 vs
0.13, IQR 0.03-.34, p>0.98).
Immunohistochemical analysis of biopsies taken from the
tumor lesions and adjacent skin at baseline and at t D 12 weeks
showed an increase in CD3C T-cell inﬁltration in the tumor in
2 of 4 responding patients (PR), and in 1 of 6 nonresponding
patients (PD), and in adjacent skin in 2 of 7 responding
patients and 2 of 10 nonresponding patients. We analyzed T-
cells cultured from these tumor biopsies (TIL) or skin biopsies
(SIL) of 15 patients (10 responders, 5 PD, all typed HLA-A1,
A2 and/or A3) for the presence of antimelanoma CD8C T-cell
responses (Figure 5 and 6). Successful T-cell outgrowth in cul-
ture from tumor biopsies taken at baseline was observed in
only 6 out of 15 patients (i.e. 4 out of 10 responding patients
and 2 out of 5 nonresponding patients), suggesting low levels
of T-cell inﬁltration into the tumor or their low proliferative
capacity. T-cell outgrowth from biopsies during MI therapy
succeeded in 11 of 15 patients (i.e. 8 out of 10 responding
patients and 3 out of 5 nonresponding patients), suggesting an
increased T cell inﬁltration or proliferative capacity upon MI
therapy. Melanoma-reactive T-cells against one or more anti-
gens were found upon MI therapy in TIL of 6 out of 8 respond-
ing patients with successful TIL growth upon MI therapy
(Figure 5A) and in TIL of 3 out of 5 nonresponding patients
(Figure 5B). The small size of the lesions treated in this study
did not allow taking multiple biopsies from a single tumor
Figure 2. Tumor regression and depigmentation. Left panels: Regression of multiple cutaneous metastases in the head and neck of patient MI-08 during MI therapy. Pho-
tographs are taken at baseline and at 6, 12 and 24 weeks of MI therapy. Right panel: Depigmentation on a non-treated area following MI therapy to cutaneous metastases
on upper body in patient MI-04.
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Figure 3. Induction of melanoma-speciﬁc antibody responses. Graphs show the antibody responses reactive with MART-1, gp100, tyrosinase, tyrosine hydroxylase or mel-
anocortin receptor MCHR1 antigens during MI therapy in 11 responding patients (A) and 10 non-responding patients (B). Patients MI-02, MI-03, MI-21 and MI-22 only
received 6 weeks of MI therapy. Antibody indices are normalized to a panel of 20 healthy controls. Antigen-speciﬁc animal antibodies were tested as positive controls.
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lesion over time, and thus biopsies at 12 weeks were taken from
different lesions than at baseline, precluding analyses of
changes in speciﬁc T-cell levels in the tumor during MI
therapy.
In contrast to tumor lesions, longitudinal analysis of local T-
cell response induction during MI therapy was more feasible in
biopsies of MI therapy-treated adjacent skin taken at 6, 12 and
16 weeks and every 12 weeks thereafter during prolonged MI
therapy. An increase in melanoma-reactive T-cells during MI
therapy was found in skin-inﬁltrating lymphocytes (SIL) from
biopsies taken at baseline or 6 weeks as compared to skin biop-
sies taken after 12 to 24 weeks, in 5 out of 6 responding patients
analyzed (Figure 6A) and in 2 out of 3 nonresponding patients
analyzed (Figure 6B). Pooled analyses of the percentages of mel-
anoma-speciﬁc T-cells in MI-therapy-treated skin of 9 patients
analyzed showed small but signiﬁcant increases in melanoma-
speciﬁc T-cell levels at baseline or 6 weeks (median 0.13, IQR
0.04–0.31) as compared to 12 weeks or later time points (median
0.23, IQR 0.06–0.47, p< 0.031).
Taken together, these results show that MI therapy effec-
tively induced melanoma-speciﬁc antibody responses and T-
cell reactivity and regression of treated cutaneous metastases in
8 of 21 patients after 12 weeks (38%) and in 11 of 21 patients
(52%) upon prolonged treatment.
Figure 4. Melanoma-speciﬁc CD8C T-cell responses in PBMC upon MI therapy. Percentages of CD8C T-cells that recognize melanoma antigens MART-1, gp100 and tyros-
inase presented by HLA-A1, -A2 or -A3 molecules. Graphs show the percentage of HLA-peptide-positive (TmC) T-cells at baseline and the maximal level reached during
MI therapy (max. T cell response) in the PBMC of responding patients (A) and nonresponding patients (B). PBMC analyses of patients MI-14 and MI-24 were not evaluable.
Legends indicate the HLA-peptide tetramers analyzed: A2/MART-1, HLA-A2-binding epitope of MART-1; A3/MART-1, HLA-A3-binding epitope of MART-1; A2/gp100(209),
HLA-A2-binding epitope 209 of gp100; A2/gp100(280), HLA-A2-binding epitope 280 of gp100; A3/gp100(17), HLA-A3-binding epitope 17 of gp100; A3/gp100(87), HLA-
A3-binding epitope 87 of gp100; A3/gp100(614), HLA-A3-binding epitope 614 of gp100; A1/TYR(140), HLA-A1-binding epitope 140 of tyrosinase; A1/TYR(243), HLA-A1-
binding epitope 243 of tyrosinase; A2/TYR, HLA-A2-binding epitope 243 of tyrosinase; A3/TYR(25), HLA-A3-binding epitope 25 of tyrosinase; A3/TYR(425), HLA-A3-binding
epitope 425 of tyrosinase.
ONCOIMMUNOLOGY e1419113-7
Discussion
In the present study, we demonstrate that topical treatment
with monobenzone and imiquimod can induce antimelanoma
immunity and local regression of inoperable cutaneous metas-
tases in stage III-IV melanoma patients. Eight (38%) out of 21
evaluable patients showed partial regression (8 patients) and
one patient had stabilization of treated cutaneous lesions at the
primary endpoint. Continued treatment strengthened the clini-
cal response, achieving complete and partial responses in 11 of
21 patients (52%). This study outcome thereby meets the
Figure 5. Melanoma-speciﬁc CD8C T-cell responses in tumor-inﬁltrating lymphocytes (TIL) upon MI therapy. Percentages of CD8C T-cells that recognize melanoma anti-
gens MART-1, gp100 and tyrosinase presented by HLA-A1, -A2 or -A3 molecules. Graphs show the percentage of HLA-peptide-positive (TmC) T-cells at baseline and dur-
ing MI therapy in tumor-inﬁltrating lymphocytes (TIL) of responding patients (A) and nonresponding patients (B). X-axis indicates the HLA-peptide tetramers analyzed
(see Figure 4) at baseline (t D 0) or upon 12 weeks of MI therapy. HLA-A3 tetramer analysis of patient MI-23 is not shown, since no T-cells grew out of biopsies during
MI therapy and only baseline TILs were analyzed. Lower part indicates patients of whom no T-cells grew out of the tumor biopsy. Legends indicate the patients analyzed.
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predetermined criteria of the study design to declare MI ther-
apy effective and worthy of further investigation.
The best clinical responses during MI therapy indicate that
the maximal induction of the antitumor response by MI ther-
apy requires more than 12 weeks. This is clearly illustrated by
the observations that 3 patients (MI-04, MI-09, MI-24)
achieved a CR upon prolonged treatment and that the clinical
response in two patients (MI-16 and MI-24) started later than
12 weeks, achieving PR and CR, respectively. Delayed clinical
beneﬁt is known from various immunotherapy regimens and
has led to the development of immune related response criteria
that take into account an initial increase in disease extent and
allow for a longer interval before a response is established.19,20
Clinical responses to MI therapy resulted in a median response
duration of 6 months. Overall survival was not determined in
this study that aimed at the local effect evaluation of MI therapy
and response duration, but will be included in future subse-
quent investigations.
MI therapy was applied as a local therapy for cutaneous
metastases, but also proved able to induce or enhance systemic
immunity against melanoma antigens. The systemic immune
activity was also demonstrated clinically by the development of
vitiligo during therapy at distant skin sites. We have previously
shown that patients with melanoma-associated vitiligo have
both antibody and T-cell immunity against melanoma anti-
gens.3,4 We also observed clinical responses in patients who did
not develop vitiligo within 12 weeks. Although we cannot
exclude that some of these patients may have developed vitiligo
at a later time point than 16 weeks, this suggests that the antitu-
mor immune response also spreads to antigens that are not
shared by melanocytes. Tumor (neo)antigens arising from
patient-speciﬁc mutations have been shown in patients that
respond well to immunotherapy.21 Further research will
address whether MI therapy can induce responses against neo-
antigens. Vice versa, the occurrence of vitiligo and T-cell
responses against melanocyte differentiation antigens (that
shared between melanoma cells and melanocytes) in nonres-
ponding patients may indicate loss of expression of these anti-
gens in the tumor, resulting in immune escape of tumor cells.
In these cases, the clinical beneﬁt will depend on the spreading
of the immune response to antigens that are expressed by
escaping tumor cells.
Local targeting of melanoma cells and immune stimulation
by MI therapy can induce priming of systemic immune
responses, but additional immune adjuvants may be necessary
to strengthen this systemic immunity. Our preclinical data has
shown that the addition of CpG greatly enhances systemic anti-
melanoma immunity induced by MI therapy.5 The results of
MI therapy described here provide a rationale for a trial to
combine MI therapy with additional immune stimulation
either by CpG or systemic therapy to enhance systemic antitu-
mor activity.
Interestingly, antibody responses against melanocyte/mela-
noma antigens were found in responding patients, which were
absent in almost all nonresponding patients. Not much is
known about melanoma-speciﬁc antibodies and their relation
to clinical outcome from literature.22-24 The majority of immu-
nomonitoring in immunotherapy studies focus on T-cell
responses, in particular speciﬁc CD8C T-cell responses using
tetramer technology or activation assays. We demonstrated
Figure 6. Melanoma-speciﬁc CD8C T-cell responses in skin-inﬁltrating lymphocytes upon MI therapy. Percentages of CD8C T-cells that recognize melanoma antigens
MART-1, gp100 and tyrosinase presented by HLA-A1, -A2 or -A3 molecules. Graphs show the percentage of HLA-peptide-positive (TmC) T-cells at baseline and during MI
therapy in skin-inﬁltrating lymphocytes (SIL) of responding patients (A) and nonresponding patients (B). Legends indicate the HLA-peptide tetramers analyzed (see
Figure 4).
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that patients with melanoma-associated vitiligo have antibodies
against gp100, tyrosinase and MART-1 in their serum while
MART-1 antibodies were undetectable in vitiligo patients,4
indicating their potential role in the melanoma-associated viti-
ligo. Antibody responses to these antigens were also found in a
stage IV melanoma patient with an exceptional disease course
of regression of brain metastases, vitiligo development and
long-term disease-free survival upon radiotherapy.3 These ﬁnd-
ings and the observation that MI therapy treated patients also
developed MART-1 antibody responses further conﬁrm the
mechanism of action of MI therapy to induce melanoma-asso-
ciated depigmentation and clinical beneﬁt to melanoma
patients.
By its speciﬁc interaction with tyrosinase, either by quinone-
modiﬁcation increasing their immunogenicity, or by epitope
spreading of the T-cell response, monobenzone can induce
immunity against a range of melanocyte/melanoma antigens
presented in patient-speciﬁc HLA types.5,25 MI therapy-
induced immunity included CD8C T-cell responses, having
direct cytotoxic antimelanoma activity, and antibody responses
that potentially amplify antimelanoma immunity by either
antibody-dependent cellular cytotoxicity (ADCC) or by bind-
ing melanoma antigens released from dying cells and increasing
their uptake and presentation by dendritic cells.26 The effect of
monobenzone is ampliﬁed by the addition of imiquimod, a top-
ical immune response modiﬁer and TLR7 ligand which stimu-
lates the production of cytokines, namely interferon-a, IL-1,
IL-6, IL-8 and TNFa and is known for its anti-viral and anti-
tumor activity.27,28 The locoregional immune activating activity
of imiquimod was demonstrated in a placebo-controlled study
of patients with high-risk primary melanoma, showing
increased CD8C T cell inﬁltration in the skin and sentinel
lymph node, but not in the peripheral blood.29 This indicates
the low efﬁcacy of imiquimod monotherapy to induce systemic
melanoma-speciﬁc immunity. Several case reports and case
series report the use of imiquimod as local monotherapy to
treat cutaneous melanoma metastases that were not eligible for
surgical excision.30 Although these reports describe promising
results, the therapeutic effect of imiquimod monotherapy on
cutaneous melanoma metastases has never been evaluated in a
clinical trial. In melanoma therapy, imiquimod has mostly
been used as an adjuvant in combination with other treatments
to enhance the induction of antitumor immunity, such as intra-
lesional IL-2 injection with or without retinoid, intralesional
BCG injection, protein or peptide vaccination, gentian violet,
5-FU, pulsed-dye laser, carbon dioxide laser, cryosurgery or
isolated limb perfusion (ILP).31-42 Imiquimod has recently also
been applied to stimulate response to ipilimumab.43
In conclusion, this clinical study shows the induction of
antimelanoma immunity and tumor regression of cutaneous
melanoma metastases by MI therapy. MI therapy is applied by
patients at home and has only transient skin toxicity, whereas
T-Vec is a costly and intensive treatment of biweekly intrale-
sional injections requiring specialized security measures for
viral medication and time consuming post-injection observa-
tions of the patient in the clinic. MI therapy induced a clinical
response in 7 patients within 12 weeks and in an additional 2
patients during prolonged therapy, which appears to be faster
than the time to response to T-Vec in injected lesions of 4.1
months.18 Moreover, multiple small lesions may be difﬁcult to
treat by intralesional injection. MI therapy may represent an
attractive option for patients that do not receive T-Vec, e.g. in
peripheral centers or when a cream based therapy is preferred.
In addition, this study provides a rationale for further clinical
investigation of MI therapy in combination with systemic
therapy.
Patients and methods
Patients
This phase 2 a study was approved by the Institutional Review
Board of the Antoni van Leeuwenhoek/ Netherlands Cancer
Institute and by the Central Committee on Research Involving
Human Subjects in the Netherlands (CCMO). (CCMO proto-
col number NL33849.031.10. The Netherlands trial register
identiﬁer: NTR 4848). All patients provided written informed
consent. The study was performed between March 2011 and
September 2014. All patients were staged prior to inclusion and
during the trial according to standard hospital staging proce-
dures. (Cross sectional staging was performed every three
months). Eligibility criteria were histologically conﬁrmed non-
ocular melanoma patients with stage IIIC-IV disease, according
to the American Joint Committee on Cancer staging classiﬁca-
tion, with multiple cutaneous metastases not eligible for surgery
or other conventional therapies,10 age 18 years, performance
status 0–1 (WHO) and a wash-out period for prior systemic
treatment of at least one month. Exclusion criteria included pri-
mary amelanotic melanoma, symptomatic brain metastases,
concomitant treatment with immunosuppressive agents and
active infections requiring antibiotics.
Study design and sample size calculation
This study was designed to establish a proof-of-concept of local
MI therapy efﬁcacy. A positive effect in patients is deﬁned as a
local clinical response (CR, PR, SD) at the primary endpoint
according to criteria described below in evaluable patients. For
the sample size calculation the A’Hern single stage phase II
design was applied, which is based on the exact binomial distri-
bution and more accurate to estimate sample size in small trials
than methods using the normal approximation.44 It was speci-
ﬁed in advance that the largest response probability which
would imply that the treatment was clearly ineffective was p0 D
0.20, and the smallest response probability that would clearly
warrant further investigation was pA D 0.45. The null hypothe-
sis H0: p  p0 D 0.20 is tested against the alternative HA: p 
pA D 0.45. At the planning of the trial it was determined, using
A’Hern’s design,44 that setting an a of 0.05 and a power of
80%, the study should include 21 evaluable patients with 8
being the minimum number of responses required for a conclu-
sion of sufﬁcient treatment efﬁcacy to justify further studies.
Treatment
Patients applied imiquimod cream (2 sachets of 250 mg, 5%
imiquimod, Aldara  Meda, Amstelveen, the Netherlands)
3 times a week on all cutaneous metastases present on an
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predetermined body area including 1–2 cm unaffected skin sur-
rounding the lesions. Monobenzone 20% (4-benzyloxyphenol,
monobenzyl ether of hydroquinone, CAS number 103–16-2,
Acros Organics, Geel, Belgium) Lanette cream FNA (Formu-
lary Dutch Pharmacists) was applied seven times a week to the
same skin area thereafter (§1.5 g). Monobenzone 20% cream
was prepared magisterially for each individual patient upon
inclusion in the study by the pharmacy of the Slotervaart Hos-
pital, Amsterdam, the Netherlands (registration numbers
101018 A and 101019 C).
Study endpoints and assessments
The primary endpoint was local clinical efﬁcacy of MI therapy
on cutaneous metastases in evaluable patients after 12 weeks of
treatment. All patients were staged by their referring physician
before entering the study. Evaluable patients were deﬁned as
patients who completed 12 weeks of MI therapy. Patients who
experienced substantial increase in number or size of treated
cutaneous lesions after 6 weeks, and who stopped MI therapy
upon consultation of their physician, were evaluated as pro-
gressive disease (PD) at the primary study endpoint of this
study. Control of systemic disease was performed by regular
check-ups following our in-house guidelines according to dis-
ease stage. In case of suspicion of inoperable distant metastases
after 6 weeks, and conﬁrmation by imaging, the patient was
referred to a medical oncologist for systemic therapy. In this
case local clinical efﬁcacy of MI therapy could not be moni-
tored further and these patients were considered not evaluable
for this study. The protocol provided for continued therapy in
case of an ongoing clinical response, stable disease or lack of
better treatment options in case of progressive disease, accord-
ing to the treating physician’s choice and patient consent. Best
clinical response during MI therapy was evaluated regardless of
MI therapy treatment duration.
The local clinical response was assessed at baseline, 6, 12 and
16 weeks and from then on every 4 weeks in case of prolonged
treatment by physical examination and detailed photography
of cutaneous lesions, and assessed according to the RECIST 1.1
criteria45: the sum of diameters of max. 5 target lesions relative
to baseline in patients with target lesions (>1 cm diameter at
baseline), deﬁning 100% decrease as complete response (CR),
>30% decrease as partial response (PR), < 30% decrease or
<20% increase as stable disease (SD) and >20% increase as
progressive disease (PD). Patients with non-target lesions
(<1 cm diameter at baseline) were assessed by the number of
lesions relative to baseline, deﬁning total disappearance of all
lesions as CR as, any decrease in number as PR, equal number
to baseline as SD, and any increase in number as PD. The
assessment of SD and PR on non-target lesions is a reﬁnement
of the non-CR/non-PD response deﬁned by the RECIST crite-
ria.45 The baseline assessment was corrected for 2 lesions that
were biopsied at baseline and after 6 weeks.
Patients were monitored for adverse events after the ﬁrst
week and further on a biweekly basis using the NCI Common
Terminology Criteria for Adverse Events (CTCAE) version 4.0
including skin and subcutaneous tissue disorders, plus analysis
of hematology, blood chemistry and S-100B serum values and
treatment compliance.
The secondary endpoint was the induction of local and sys-
temic antimelanoma immunity by MI therapy. A 6-mm biopsy
of a cutaneous lesion, a 4-mm biopsy of adjacent, treated skin
and 50 ml peripheral blood were taken at baseline and every
6 weeks for immunomonitoring purposes.
Melanoma-speciﬁc antibody analysis
Antibodies in serum samples were detected using radioligand-
binding assays (RBA), as described previously.46 This technique
is at least as sensitive as ELISA and more sensitive than West-
ern blotting.47 Brieﬂy, plasmids pcDNA3-TH, pcDNA3-TYR,
pcDNA3-PMEL17, pcDNA3-MCHR1 and pcDNA3-Melan-A
(MART-1) were used according to the manufacturer in an in
vitro TnTT7-coupled Reticulocyte Lysate System (Promega,
Southampton, UK) with [35S]-methionine to produce radiola-
beled full-length proteins TH, tyrosinase, gp100, MCHR1 and
MART-1, respectively.46 Radiolabeled antigens were then used
in RBAs with patient and healthy control (n D 20) sera at a
1:100 dilution, as described previously.46 An antigen-speciﬁc
animal antibody was included in each RBA as a positive con-
trol. In each RBA, an antibody index for each serum was calcu-
lated as the counts per minute immunoprecipitated by tested
serum divided by the mean counts per minute immunoprecipi-
tated by 20 healthy control sera. In each experiment, the upper
limit of normal was calculated as mean antibody index of con-
trols plus 3 times the standard deviation (SD) and used as a
threshold value for positivity. Increases in antibody indexes
during therapy were analyzed statistically using the nonpara-
metric Wilcoxon signed rank test of paired data (IBM SPSS Sta-
tistics version 22).
Isolation and culture of peripheral blood mononuclear
cells (PBMC), tumor-inﬁltrating lymphocytes (TIL) and skin-
inﬁltrating lymphocytes (SIL)
We acknowledge the concept of the minimal information about
T-cell assays (MIATA) reporting framework for human T-cell
assays.48 Peripheral blood was collected in Vacutainer blood
collection tubes containing heparin (Greiner Bio-One, Alphen
aan de Rijn, the Netherlands). PBMC were isolated by Ficoll
gradient centrifugation (Lymphoprep, Fresenius Kabi, Zeist,
the Netherlands), as described previously.49 Tumor-inﬁltrating
lymphocytes (TIL) and skin-inﬁltrating lymphocytes (SIL)
were obtained, as described previously.50 Biopsies of 6 mm or
4 mm diameter were taken from melanoma lesions or adjacent
skin, respectively, transported to the AMC on ice in sterile
tubes containing Phosphate Buffered Saline (Fresenius Kabi)
and processed within 6 hours. Biopsies were cultured in a
humidiﬁed atmosphere at 37 C and 5% CO2 in 24-wells plates
with 1 ml/well Iscoves modiﬁed Dulbecco’s Medium (IMDM),
supplemented with 10% heat-inactivated human serum type
AB (Lonza, Basel, Switzerland), 40 U/ml IL-2 (Proleukin,
Novartis Pharma, Arnhem, The Netherlands), 5 ng/ml IL-15
(PeproTech EC, London, UK), 15 mg/ml gentamycin (Duchefa,
Haarlem, the Netherlands), 2 mM L-glutamine, 50 U/ml peni-
cillin and 50 mg/ml streptomycin (Gibco Life Technologies,
Thermo Fisher Scientiﬁc, Landsmeer, The Netherlands). In
addition, 1.25 ml/ml anti-CD3/CD28 monoclonal antibody-
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coated T-cell expander beads (Dynabeads, Life Technologies,
Thermo Fisher Scientiﬁc, Landsmeer, the Netherlands) were
added at day 0 to promote T-cell outgrowth and expansion.
PBMC were cultured similarly during approximately 3 weeks
to obtain cultured peripheral blood lymphocytes (PBL), keep-
ing equal culture conditions and time periods for PBL, TIL and
SIL of each patient until analysis.
HLA typing
HLA typing of patients was performed on PBL, cultured from
peripheral blood without cryopreservation, by ﬂow cytometry
using ﬂuorescein isothiocyanate (FITC)-conjugated mouse
anti-human HLA-A2-speciﬁc monoclonal antibody (mAb)
(BD Biosciences, Breda, the Netherlands) and biotinylated
HLA-A1/A36-speciﬁc antibody (BIH0331), biotinylated HLA-
A2-speciﬁc antibody (BIH0648) or biotinylated HLA-A3-spe-
ciﬁc antibody (BIH0269, all from One Lambda Inc., Canoga
Park, CA), followed by allophycocyanin (APC) conjugated
streptavidin (Biolegend, ITK Diagnostics, Uithoorn, The Neth-
erlands) to detect biotinylated antibody binding. Cells were
acquired on a FACS Canto II (Beckton Dickinson, Breda, the
Netherlands), and analyzed by FlowJo Software (Treestar, Ash-
land, OR).
Detection of melanocyte-speciﬁc T-cells in peripheral
blood lymphocytes and melanoma tissues
The protocol of the Laboratory of Experimental Dermatology at
the AMC for HLA-peptide tetramer analysis of human T-cell
responses was harmonized in 2013 with the maximum overall
proﬁciency score by participating in the Immudex MHC Multi-
mer Proﬁciency panel initiated by the Association of Cancer
Immunotherapy Europe (CIMT)51 and the Cancer Immuno-
therapy Consortium (CIC). HLA-A1-, HLA-A2- and HLA-A3/
peptide tetramers containing peptides of the melanocyte differ-
entiation antigens tyrosinase, gp100, MART-1 were used to
detect antigen speciﬁcity of T-cells isolated from treated areas
of the tumor (TIL), and adjacent skin (SIL), or peripheral blood
(PBMC and cultured PBL), as previously described.50 Brieﬂy,
R-phycoerythrin (PE)- or APC-conjugated HLA-A1,HLA-A2-
and HLA-A3/peptide complex tetramers were synthesized for
the antigens HLA-A1: tyrosinase145–156, tyrosinase243–251;
HLA-A2: tyrosinase369–377, gp100280–288, gp100209–217, MART-
126–35 (modiﬁed position 27 (A>L)) and HLA-A3: gp10017–25,
gp10087–95 gp100614–622, tyrosinase25–33, tyrosinase425–434 and
MART-142–50 HLA/peptide. T-cells cultured from peripheral
blood or biopsies were used for analyses without cryopreserva-
tion. HLA-peptide tetramer analyses of cultured T cells were
performed at least 14 days after the CD3/28 antibody stimula-
tion. PBMC were cryopreserved in culture medium containing
50% Fetal Calf Serum (FCS) and 10% DMSO in vapor-phase
liquid nitrogen storage for approximately 3 weeks until analy-
sis. Viability of thawed PBMC for analysis was 50–80%.
Approximately 0.5106 cells were used per staining. T-cells
were incubated with HLA-A1, -A2, or -A3/peptide tetramers in
PBS, 1% Bovine Serum Albumin (BSA), and 0.5% sodium azide
(this standard FACS buffer was previously tested for optimal
assay performance) for 20 minutes at room temperature.
Subsequently, cells were counterstained with FITC-conjugated
mouse anti-human CD8 mAb and APC-conjugated mouse
anti-humans CD3 mAb (both from Biolegend, ITK Diagnos-
tics, Uithoorn, the Netherlands). Antibody and tetramer bind-
ing to T-cells was analyzed by ﬂow cytometry (FACS Canto II,
Beckton Dickinson). The combination of ﬂuorochromes for
multicolor ﬂow cytometry was chosen based on optimal perfor-
mance on the FACS Canto II in previous tests.50 Data were ana-
lyzed using Flow Jo software (Treestar, Ashland, OR), by life
gating of the lymphocyte population on FSC-A/SSC scatter
plots, exclusion of cell doublets on FSC-H/SSC scatter plots,
compensation of ﬂuorescent signal overﬂow and gating of
CD3C cells. The percentages of CD3CCD8C TmC cells of
total CD8C T-cells were calculated from CD8 versus tetramer-
binding dot plots of CD3C gated populations. At least 300,000
cells were acquired in total for each sample. The range of tetra-
mer-binding CD8C T-cells found varied between 0.01 and
4.78%, of which percentages above 0.1% of total CD8C T-cells
were considered as a positive percentage. This threshold was
predeﬁned, based on earlier analyses.50 The induction of an
immune response was deﬁned per tetramer as a positive per-
centage of tetramer-binding T-cells with an increase of at least
0.1% above the percentage of tetramer-binding CD8C T-cells
at baseline. The number of antigen-speciﬁc T-cell responses
was analyzed per patient. Changes in percentage of antigen-
speciﬁc T-cell responses per tissue (PBMC, PBL, TIL, SIL) from
baseline to the primary endpoint (12 weeks) or maximal T-cell
response during MI therapy were analyzed statistically in all
patients or in subgroups of responding or nonresponding
patients, using the nonparametric Wilcoxon signed rank test of
paired data (IBM SPSS Statistics version 22).
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